Telemonitoring of blood pressure self measurement in the OLMETEL study

Blood Pressure Monitoring

Volumn 9, Issue 6, 2004, Pages 321-325

  Mengden, Thomas ^a,d   Ewald, Silke ^b   Kaufmann, Stefanie ^b   Vor Dem Esche, Johannes ^c   Uen, Sakir ^a   Vetter, Hans ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b Daiichi Sankyo Europe GmbH   (Germany)

^c TeleMed Project GmbH   (Germany)

^d Div of Hypertension and Vasc Med   (Germany)

Author keywords

Blood pressure self measurement; Hypertension; Olmesartan medoxomil; Telemonitoring

Indexed keywords

OLMESARTAN;

ADULT; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CLINICAL PRACTICE; CONFERENCE PAPER; DEVICE; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FEVER; HEADACHE; HUMAN; HYPERTENSION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RELIABILITY; REMOTE SENSING; SELF MONITORING; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; TECHNIQUE; TELEMONITORING; TELEPHONE TELEMETRY; VOMITING;

ADULT; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE MONITORING, AMBULATORY; CLINICAL TRIALS; HUMANS; HYPERTENSION; IMIDAZOLES; SELF CARE; TELEMEDICINE; TETRAZOLES;

EID: 17044428618     PISSN: 13595237     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126097-200412000-00010     Document Type: Conference Paper

References (24)

1. Mengden T, Uen S, Baulmann J, Vetter H. Significance of blood pressure self-measurement as compared with office blood pressure measurement and ambulatory 24-hour blood pressure measurement in pharmacological studies. Blood Press Monit 2003; 8:169-172.
2. Ménard N, Linhart A, Weber JL, Paria C, Herve C. Teletransmission and computer analysis of self-blood pressure measurements at home. Blood Press Monit 1996; 1(Suppl 2);S63-S67.
3. Kleinen HD, Harshfield GA, Pickering TG, Devereux RB, Sullivan PA, Marion RM, et al. What is the value of home blood pressure measurement in patients with mild hypertension? Hypertension 1984; 6:574-578.
4. Mengden T, Vetter H, Tislér A1 Illyés M. Telemonitoring of home blood pressure. Blood Press Monit 2001; 6:185-189.
5. Friedman RH, Kazis LE, Jette A, Smith MB, Stollerman J, Torgerson J, et al. A telecommunications system for monitoring and counselling patients with hypertension. Impact on medication adherence and blood pressure control. Am J Hypertens 1996; 9(4 Pt 1):285-292.
6. Rogers MA, Small D, Buchan DA, Butch CA, Stewart CM, Krenzer BE, et al. Home monitoring service improves mean arterial pressure in patients with essential hypertension. A randomized, controlled trial. Ann intern Med 2001; 134:1024-1032.
7. Parati G, Omboni S, Paintoni L, Andolfo S, Angioni L, Belforti S, et al. Telemonitoring of home blood pressure improves blood pressure control in hypertension. J Hypertens 2004; 22(Suppl 2):S137(abstract).
8. Warner GT, Jarvis B. Olmesartan medoxomil. Drugs 2002; 62: 1345-1353.
9. Ball KJ, Williams PA, Stumpe KO. Relative efficacy of an angiotensin II antagonist compared with other antihypertensive agents. Olmesartan medoxomil versus antihypertensives. J Hypertens 2001; 19(Suppl 1): S49-S56.
10. Chrysant SG, Marbury TC, Robinson TD. Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension. J Hum Hypertens 2003; 17:425-432.
11. Stumpe KO, Ludwig M. Antihypertensive efficacy of olmesartan compared with other antihypertensive drugs. J Hum Hypertens 2002; 16(Suppl 2): S24-S28.
12. Oparii S, Williams D, Chrysant SG, Marbury TC, Neutel J. Comparative efficacy of oimesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens 2001; 3: 283-291.
13. Brunner HR, Stumpe KO, Januszewicz A. Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil assessed by 24-hour ambulatory blood pressure monitoring in patients with essential hypertension. Clin Drug Invest 2003; 23:419-430.
14. Puchler K, Laeis P, Stumpe KO. Blood pressure response, but not adverse event incidence, correlates with dose of angiotensin II antagonist. J Hypertens 2001; 19(Suppl 1):S41-S48.
15. Neutel JM. Clinical studies of CS-866, the newest angiotensin II receptor antagonist. Am J Cardiol 2001; 87:37C-43C.
16. Chilman-Blair K, Rabasseda X. Olmesartan, an AT1-selective antihypertensive agent. Drugs Today 2003; 39:745-761.
17. Illyés M, Mengden T, Tislér A. The virtual hypertension clinic. Blood Press Monit 2002; 7:67-68.
18. Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21:1011-1053.
19. Pierdomenico SD, Mezzetti A, Lapenna D, Guglielmi MD, Mancini M, Salvatore L, et al. 'White-coat' hypertension in patients with newly diagnosed hypertension: evaluation of prevalence by ambulatory monitoring and impact on cost of health care. Eur Heart J 1995; 16:692-697.
20. Segre CA, Ueno RK, Warde KR, Accorsi TA, Miname MH, Chi CK, et al. White-coat hypertension and normotension in the League of Hypertension of the Hospital das Clinicas, FMUSP: prevalence, clinical and demographic characteristics. Arq Bras Cardiol 2003; 80:117-126.
21. Schwocho LR, Masonson HN. Pharmacokinetics of CS-866, a new angiotensin Il receptor blocker, in healthy subjects. J Clin Pharmacol 2001; 41:515-527.
22. Mengden T, Battig B, Schubert M, Jeck T, Weisser B, Buddeberg C, et al. Comparison of casual, ambulatory and self-measured blood pressure in a study of nitrendipine vs bisoprolol. Eur J Clin Pharmacol 1992; 42: 569-575.
23. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL. Jr, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560-2572.
24. Greathouse M. A review of olmesartan medoxomil monotherapy: antihypertensive efficacy similar to that of other angiotensin II receptor blocker/hydrochlorothiazide combinations? Congest Heart Fail 2002; 8:313-320.